Success Metrics

Completion Rate
0%(0/1)
Active Trials
7(47%)
Terminated
1(7%)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_1
8
53%
Ph phase_2
5
33%

Phase Distribution

8

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
8(57.1%)
Phase 2Efficacy & side effects
5(35.7%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

15

all time

Status Distribution
Active(11)
Terminated(1)
Other(3)

Detailed Status

Recruiting5
Not yet recruiting4
unknown3
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
7
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (57.1%)
Phase 25 (35.7%)
N/A1 (7.1%)

Trials by Status

unknown320%
active_not_recruiting213%
recruiting533%
terminated17%
not_yet_recruiting427%

Recent Activity

7 active trials
Showing 5 of 15
not_yet_recruitingphase_1

Study of ABO2102 in KRAS-Mutated Solid Tumors

NCT07455617
recruitingphase_1

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT06530251
recruitingnot_applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

NCT06353646
recruitingphase_1

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

NCT06956716
not_yet_recruitingphase_1

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

NCT06888674
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07455617Phase 1

Study of ABO2102 in KRAS-Mutated Solid Tumors

Not Yet Recruiting
NCT06530251Phase 1

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Recruiting
NCT06353646Not Applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Recruiting
NCT06956716Phase 1

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Recruiting
NCT06888674Phase 1

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Not Yet Recruiting
NCT06888648Phase 1

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Not Yet Recruiting
NCT04836728Phase 2

Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

Active Not Recruiting
NCT04840355

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

Recruiting
NCT06523049Phase 2

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Not Yet Recruiting
NCT05804526Phase 1

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Recruiting
NCT04326153Phase 2

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer

Active Not Recruiting
NCT04653389Phase 2

Perioperative Therapy for Hepatocellular Carcinoma

Terminated
NCT04567069Phase 1

Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment

Unknown
NCT03987867Phase 1

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Unknown
NCT04371796Phase 2

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Unknown

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15